
LILRB1 CAR-T therapy may overcome CD19 resistance. Using cell surface proteomics on high-risk B-ALL samples, researchers identified LILRB1 as a stable antigen post-CD19/CD20 therapies. LILRB1 CAR-T cells demonstrated potent, antigen-specific activity against B-ALL, B-NHL, and AML in vitro and in vivo, including CD19 CAR-T–resistant cases. These findings support LILRB1 as a promising target for next-gen CAR-T immunotherapy in relapsed or refractory hematologic malignancies.
Like
Save
Share